Biogen Completes Acquisition of Apellis Pharmaceuticals

Biogen completed its acquisition of Apellis Pharmaceuticals, adding EMPAVELI and SYFOVRE, which generated $689 million in net product revenue in 2025. The deal is expected to be accretive to Biogen’s non-GAAP diluted EPS in 2027 and to materially lift EPS CAGR through the end of the decade, while updated guidance will come with the Q2 earnings report in July. Approximately 105.7 million shares, or 82.4% of Apellis shares outstanding, were tendered, and Apellis stock has ceased trading on Nasdaq.

Analysis

This is less a classic accretive tuck-in and more a balance-sheet-funded de-risking of Biogen’s revenue mix. The market should increasingly value BIIB on a higher-quality cash flow stream because the acquired franchises are already commercial, don’t require binary readout risk to contribute, and give management a way to smooth the post-MS/biosimilar transition over the next 6-18 months. The bigger second-order winner is Biogen’s pipeline optionality: owning an established nephrology sales force meaningfully lowers the cost and time-to-penetration for felzartamab if the 2027 data are positive.

The key swing factor is whether investors treat the acquired assets as durable growth or as peak-to-midcycle assets facing erosion/label friction. In my view, the OTC-style setup in the stock is that the market will initially underweight integration risk because the transaction is closed, but the real risk sits in execution: cross-selling into nephrology, maintaining physician trust around safety monitoring, and preventing commercial distraction from core neurology. If those pieces slip, the EPS accretion story can get deferred, and the stock may give back part of the “certainty premium” it just earned.

Competitively, this should pressure smaller complement-focused players and raise the bar for any would-be entrants in the GA and rare kidney spaces. The more important ripple effect is on deal economics across mid-cap biotech: strategic buyers now have a live precedent for paying up for commercial assets plus pipeline adjacency, which could compress risk premiums for assets with real sales and a credible expansion runway. The contrarian point is that the market may be too focused on headline accretion and not enough on the fact that these products still carry meaningful pharmacovigilance and utilization-friction constraints, which can cap revenue velocity even inside a larger parent.

Key Decisions for Investors

• Long BIIB on a 3-6 month horizon into Q2 guidance; use pullbacks to add. Risk/reward skews favorably if management lifts 2027 EPS and mid-decade CAGR targets, with downside mainly from integration and guidance reset risk.
• Buy BIIB Jan-2027 calls or call spreads to express the optionality around felzartamab launch readiness and the 2027 Phase 3 readout. The asymmetry is best if the market underprices the pipeline leverage from the acquired nephrology infrastructure.
• Avoid chasing APLS-related residual event-driven exposure; the close removes most of the idiosyncratic arb, and remaining value is now embedded in BIIB. Any post-close spread dislocation should be used to rotate into BIIB rather than hold synthetic upside.
• Relative value: long BIIB / short a basket of slower-growth large-cap neuro peers over 2 quarters. Biogen now has a clearer path to near-term revenue support and should screen better on forward EPS durability than legacy-only names.